Faculty Opinions recommendation of Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

2019 ◽  
Author(s):  
Mario Cazzola
Keyword(s):  
Dual Therapy ◽  
Once Daily

scholarly journals Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen

2020 ◽  
Author(s):  
Romain Palich ◽  
Clotilde Allavena ◽  
Gilles Peytavin ◽  
Cathia Soulie ◽  
Roland Tubiana ◽  
...  
Keyword(s):  
Success Rate ◽  
Primary Outcome ◽  
Viral Suppression ◽  
Dual Therapy ◽  
Open Label ◽  
Once Daily ◽  
Drug Concentrations ◽  
Highly Effective ◽  
Lost To Follow Up

Abstract Background Etravirine/raltegravir dual therapy has been shown to be highly effective as a twice-daily (q12h) regimen in suppressed HIV-infected patients enrolled in the ANRS-163 study. Objectives As a once-daily (q24h) regimen is easier for daily life, we aimed to evaluate the capacity of etravirine/raltegravir (400/800 mg) q24h to maintain viral suppression in patients on etravirine/raltegravir q12h. Methods Patients on a suppressive etravirine/raltegravir q12h regimen for at least 96 weeks were switched to etravirine/raltegravir q24h in this prospective, multicentre, open-label, single-arm study. Primary outcome was the rate of virological failure (VF: confirmed pVL >50 copies/mL, single pVL >400 copies/mL or single pVL >50 copies/mL with ART change) at Week 48 (W48). Secondary outcomes included treatment strategy success rate (no VF and no treatment discontinuation), regimen tolerability, plasma drug concentrations and resistance profile in the case of VF. Results A total of 111 patients were enrolled, with a median (IQR) age of 57 years (52–62), CD4 count of 710 cells/mm3 (501–919) and viral suppression for 7.9 years (5.9–10.7). Two patients experienced viral rebound at W24 and W48, leading to a VF rate of 2.0% (95% CI 0.5–7.8) at W48, associated with INSTI resistance in one case. Both had past NNRTI mutations. Ten patients discontinued treatment for adverse events (n = 2), investigator or patient decisions (n = 3), lost to follow-up (n = 3), death (n = 1) or pregnancy (n = 1). Overall, the strategy success rate was 89% (95% CI 81.5–93.6) at W48. In a subgroup of 64 patients, median (IQR) plasma C24h concentrations were 401 ng/mL (280–603) for etravirine and 62 ng/mL (31–140) for raltegravir. Conclusions Switching patients virally suppressed on etravirine/raltegravir q12h to the same regimen but given q24h was highly effective in maintaining virological suppression in HIV-infected patients.

Pharmacokinetic Study of Dual Therapy With Raltegravir 400 mg Twice Daily and Darunavir/Ritonavir 800/100 mg Once Daily in HIV-1–Infected Patients

2013 ◽  
Vol 35 (4) ◽  
pp. 552-556 ◽  
Author(s):  
Maria Martínez-Rebollar ◽  
Ana Muñoz ◽  
Iñaki Pérez ◽  
Susana Hidalgo ◽  
Mercè Brunet ◽  
...  
Keyword(s):  
Pharmacokinetic Study ◽  
Dual Therapy ◽  
Once Daily ◽  
Hiv 1

scholarly journals Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

2018 ◽  
Vol 378 (18) ◽  
pp. 1671-1680 ◽  
Author(s):  
David A. Lipson ◽  
Frank Barnhart ◽  
Noushin Brealey ◽  
Jean Brooks ◽  
Gerard J. Criner ◽  
...  
Keyword(s):  
Dual Therapy ◽  
Once Daily

Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy

2020 ◽  
Vol 75 (11) ◽  
pp. 3327-3333
Author(s):  
Leonardo Calza ◽  
Vincenzo Colangeli ◽  
Marco Borderi ◽  
Diletta Testi ◽  
Bianca Granozzi ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Dual Therapy ◽  
Comparable Efficacy ◽  
Good Tolerability ◽  
Once Daily ◽  
Hiv Rna ◽  
Group A ◽  
Group B ◽  
The Cost

Abstract Background Antiretroviral dual regimens including lamivudine and one boosted PI or dolutegravir are warranted in order to optimize combination ART (cART), prevent long-term toxicity and reduce the cost of treatments. Objectives We hypothesized that a maintenance dual regimen of lamivudine plus raltegravir would be effective and as well tolerated as the dual maintenance combination of lamivudine plus dolutegravir. Methods We performed an observational, retrospective study of HIV-infected patients on suppressive ART who switched to a dual regimen containing lamivudine 300 mg once daily plus raltegravir 1200 mg once daily or dolutegravir 50 mg once daily. Results In total, 109 patients (79 men; mean age 46.4 years; mean CD4+ T lymphocyte count 605 cells/mm3) were enrolled. Overall, 50 subjects switched to lamivudine plus raltegravir (Group A) and 59 to lamivudine plus dolutegravir (Group B). After 12 months, 45 patients (90%) in Group A and 52 (88.1%) in Group B had HIV RNA <20 copies/mL. No patients had severe adverse effects in either group, and the percentages of patients with mild adverse effects were comparable, except for a higher incidence of headache and sleeping disturbances in Group B than in Group A (30.5% versus 14%, P < 0.001). A comparable and non-significant weight increase was reported in both groups (+1.91 kg in Group A and +2.28 kg in Group B). Conclusions In our study, dual therapies containing lamivudine plus raltegravir or dolutegravir in virologically suppressed patients showed high and comparable efficacy, as well as good tolerability.

Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient

2016 ◽  
Vol 28 (7) ◽  
pp. 726-728 ◽  
Author(s):  
Massimiliano Lanzafame ◽  
Emanuela Lattuada ◽  
Stefano Nicolè ◽  
Fabio Rigo ◽  
Giulia Cucchetto ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Infected Patient ◽  
Viral Suppression ◽  
Dual Therapy ◽  
Once Daily ◽  
Hiv Rna ◽  
Highly Active ◽  
Toxicity Effects

Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as ‘maintenance’ antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as ‘maintenance antiretroviral therapy’, with persistence of viral suppression.

scholarly journals Comparison of Rupatadine Monotherapy and Combined Levocetirizine with Ranitidine Dual Therapy for the Treatment of Chronic Idiopathic Urticaria

2021 ◽  
Vol 6 (2) ◽  
pp. 01-07
Author(s):  
Richmond Ronald Gomes ◽  
Kaniz Rahman ◽  
Dilruba Aktar ◽  
SM Matiur Rahman ◽  
Sharif M Rahman
Keyword(s):  
Adverse Effects ◽  
Relapse Rate ◽  
Conventional Treatment ◽  
Combined Therapy ◽  
Dual Therapy ◽  
Similar Efficacy ◽  
Chronic Idiopathic Urticaria ◽  
Once Daily ◽  
Group A ◽  
Group B

Background: Effective treatment for chronic idiopathic urticaria (CIU) with conventional combined therapy comprising H1 and H2 antihistamine is effective but associated with high relapse rate. Newer H1 blocker rupatadine alone is similarly effective with less relapse rate. Also it is convenient for the patient as similar efficacy is obtained with single dosage compared to 3 times dosing in combined therapy. This study was done to compare the traditional treatment with levocetirizine and ranitidine to a newly introduced antihistamine rupatadine for CIU. Materials and Methods: The study was a hospital based prospective randomized control trial among 40 patients with CIU in Dermatology and Venereology department of Bangabandhu Sheikh Mujib Medical University(BSMMU), Dhaka from April 2020 to September 2020.Forty patients of CIU were randomly enrolled into two equal groups (group A and B). Patients of group-A were treated with 5 mg of levocetirizine once daily plus 150 mg of ranitidine twice orally daily and group-B were treated with rupatadine 10 mg once daily for one month. The efficacy was assessed 1st and 4th week during treatment and 4 weeks after completion of treatment by observing reduction of itching, regression of the size and shape of lesions and appearance of new lesions. Adverse effects and patient satisfaction were also noted. Results: 75% patients in group A and 80% patients in group B responded to treatment (p>0.05).80% in group A and 85% in group B showed improvement in itching in the first week (p>0.05). . At the end of 4 weeks 95% showed improvement in each group. Appearance of new lesions in first week was 10% and 5% (p>0.05) and at 4th week, 5% and 0% respectively (p>0.05). 75% in group A and 80% in group B had regression in their lesions at the end of first week (p>0.05). At the end of 4th week, it was 85% and 90% (p>0.05). 40% in group A and 25% in group B had relapse of itching at follow up (p<0.05). Relapse of lesions were 35% and 20% (p<0.05). Overall occurrence of side effects (3 compared to 1) was more in group A. Conclusion: The result of the present study show that both conventional treatment with levocetirizine and ranitidine combination and newer agent rupatadine alone has similar efficacy in reducing clinical sign and symptoms of CIU. But rupatadine has significantly reduced the relapse rate and so it is a more efficacious and also safer option with less adverse effects for the treatment of CIU in comparison to conventional treatment. Rupatadine is also more convenient option for patients in term of dosage schedule.

Sign in / Sign up

Export Citation Format

Share Document